Our Mission
OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by developing monoclonal antibodies and other agents that target the biologic pathways critical to tumor initiating cells, also known as "cancer stem cells". We are leveraging our understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.
Latest News
- April 3, 2012OncoMed Pharmaceuticals Recaps New Data Presented at AACR
- January 9, 2012 OncoMed Pharmaceuticals Promotes Dr. Jakob Dupont to Chief Medical Officer
- October3, 2011 OncoMed Pharmaceuticals Names Jakob Dupont VP Clinical Research
- April 28, 2011 OncoMed Pharmaceuticals Announces FDA Clearance to Commence Phase 1 Testing of Anti-Cancer Stem Cell Therapeutic OMP-18R5

